LipoCalm® – liquid phospholipid-based dietary supplement with PharmaGABA® and botanical extracts

LipoCalm® is a liquid dietary supplement from Quicksilver Scientific developed in a phospholipid-based formulation with PharmaGABA® and carefully selected botanical ingredients. The product comes in a 50 mL bottle and is formulated as a liquid supplement for adults who want a practical alternative to traditional capsules and tablets. Quicksilver describes the product as a phospholipid-based or liposomal formulation, with 25 servings per bottle.

The formulation combines gamma-aminobutyric acid from fermented PharmaGABA® with skullcap, passion flower and chamomile flower oil in a liquid base with phospholipids. This provides a product with both modern delivery technology and plant-based ingredients in one integrated solution. LipoCalm® has been developed for adults who want a liquid dietary supplement with phospholipids, PharmaGABA® and botanical extracts in a user-friendly format.

Target group
The product is formulated for adults. The manufacturer states that pregnant, lactating women and people planning pregnancy should consult a doctor before use.

Ingredients
LipoCalm® contains a proprietary blend of highly purified phospholipids, gamma-aminobutyric acid such as PharmaGABA®, liquid herbal extract of skullcap (Scutellaria lateriflora), liquid extract of passion flower (Passiflora incarnata) and chamomile flower oil. Other publicly listed ingredients include water, glycerin, ethanol, and vitamin E. Publicly available manufacturer information lists the total amount for the proprietary blend, but not separate amounts for each active ingredient.

Use and recommended intake
Recommended use from the manufacturer is 4 pumps per time, corresponding to 1 portion. The liquid is held in the mouth for 30–90 seconds before being swallowed. The product is taken on an empty stomach, at least 10 minutes before meals. The manufacturer also states that the contents should be used within 60 days of opening.

Technical details
LipoCalm® is supplied in a 50 mL bottle. The portion size is 2 mL, corresponding to 4 pumps, and the bottle contains 25 portions. The proprietary blend is declared at 350 mg per serving. Quicksilver refers to the product as a phospholipid-based or liposomal formulation, but publicly available material does not provide details such as particle size, pH, density or corresponding technical specifications.

Allergens and special considerations
Publicly available product information does not show a complete allergen profile according to EU standards. The product contains ethanol and botanical extracts. Full raw material specification, allergen status and any documentation of the absence of specific allergens should be confirmed against the manufacturer's documentation before finalizing the Norwegian market text and label.

Storage
Store dry and cool, protected from direct sunlight and out of the reach of children. The manufacturer recommends that the product be used within 60 days of opening.

Reservation
For adults only. The recommended daily dose should not be exceeded. Dietary supplements should not replace a varied diet and a healthy lifestyle. Keep out of the reach of children. Pregnant women, breast-feeding women and people who use medicines or are planning to become pregnant should consult a doctor before use. Uno Vita AS does not claim that the product can prevent, treat or cure disease.

Disclaimer
Uno Vita uses artificial intelligence for analyses, structuring and text production. The information is only intended as general product information and not as medical advice. Although the text has been prepared with great care, errors or omissions may occur. All information should therefore be critically assessed and checked against manufacturer data, current regulations and professional sources before publication or use.

Freedom of expression and right to information
Uno Vita reserves the right to disseminate publicly available research and general information about nutrition, ingredients and health and wellness technologies in line with national and international principles on freedom of expression and freedom of information, including UN Article 19, ICCPR Article 19 and the Constitution § 100.